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Expression of the human pancreatic secretory trypsin inhibitor (PSTI) gene was examined in 24 cases of 
neoplastic tissues by Northern blot analyses. In three cases of lung adenocarcinoma nd one case of sigmoid 
colon polyp, we detected transcripts which hybridized to the human PSTZ cDNA probe. cDNA libraries 
were constructed using mRNAs of the two PSTI-positive tumor tissues. Two PSTZ cDNA clones were ob- 
tained from each sample. Sequencing analyses showed that they were completely identical with that of pan- 
creatic PSTI cDNA which had been reported [(1985) B&hem. Biophys. Res. Commun. 132, 605-6121. 
Southern blot analyses showed that the elevated expression of PSTZ in neoplastic tissues was accompanied 
by neither PSTI gene amplification nor rearrangements. 
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1. INTRODUCTION 
The pancreatic secretory trypsin inhibitor 
(PSTI) is a single chain polypeptide which is 
secreted by mammalian pancreatic acinar cells into 
pancreatic juice. Its physiological role has been 
considered to be to prevent premature trypsin- 
catalyzed activation of zymogens within the pan- 
creas and the pancreatic duct. Material(s) 
crossreacting with anti-PST1 antibody is (are) pro- 
duced and secreted into blood vessels. The level of 
such an antigen increases upon severe injury or 
surgery [1,2] and under inflammatory conditions 
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The nucleotide sequence presented here has been submit- 
ted to the EMBL/GenBank database under the accession 
number YOO705 
[3]. The serum PST1 level remains within the nor- 
mal range even after total pancreatectomy [4]. 
These findings strongly suggest hat PST1 is pro- 
duced in extrapancreatic tissues, although its func- 
tion has not been understood. Interestingly, some 
malignant diseases have also been associated”with 
high PST1 levels [5]. Huhtala et al. [6] found such 
material in the urine of a patient with ovarian 
cancer, and Ogawa et al. [7] detected a similar 
material in various cancer cells. These findings 
suggest hat some tumor cells may produce PSTI, 
although no direct evidence is available. If this is 
the case, the question remains of whether the 
‘PSTI’ produced in tumor cells is identical with 
that produced in the pancreas or is (a) different 
material(s) that is (are) related to PSTI. We in- 
itiated studies to clarify these points by isolating 
‘PSTI' cDNA clones from neoplastic tissues and 
characterizing its sequence. The results show that 
this material is identical with that produced in the 
pancreas, which was described by Yamamoto et al. 
PI. 
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2. MATERIALS AND METHODS 
2.1. Preparation of mRNA 
The neoplastic tissues are listed in table 1. They 
were removed in surgical operations, immediately 
frozen in liquid nitrogen and stored at -70°C. 
Total cellular RNA was isolated essentially as 
described [9]. mRNA was purified from the total 
RNA by repeated passages through an oligo(dT) 
cellulose (type 7, Pharmacia Co., Sweden) column. 
2.2. Preparation of PST1 cDNA probe 
A 303 bp XhoI-San fragment of pYIAM82 [lo] 
was used as a probe. This DNA covers the entire 
amino acid coding region of the PSTI cDNA [8]. 
A “P-labeled cDNA probe (spec. act. 4-8 x 
lo8 cpm/pg) was prepared by the random priming 
method [l l] using [a-32P]dCTP (Amersham, 
3000 Ci/mmol; 1 Ci = 37 GBq). 
2.3. Construction of cDNA libraries and screening 
for PST1 clones 
cDNA libraries were constructed from two 
mRNA samples, as prepared from a lung 
adenocarcinoma (LC 19), and a sigmoid colon 
polyp (CC 5). Double-stranded cDNAs were 
prepared and then ligated to hgtl0 with EcoRI 
linkers as described in [ 121. To screen for PSTI 
cDNA clone, plaque hybridization using a nylon 
filter (Gene Screen Plus, NEN, USA) was per- 
formed as described in [ 131. 
2.4. cDNA sequencing analysis 
Nucleotide sequence analysis was performed by 
the chain termination method [14] using 
bacteriophage M13mp19. 
2.5. Southern and Northern blot hybridizations 
10 pg high molecular mass DNA prepared from 
tumor tissues or from a non-tumorous portion of 
LC 19 was digested twice with restriction enzymes 
(Takara Shuzo, Kyoto, Japan), electrophoresed in 
0.7% agarose gel and transferred to a nylon filter 
[ 151. mRNA was denatured by heating at 65°C for 
15 min in 50% (v/v) formamide, electrophoresed 
in a 1% agarosei2.2 M formaldehyde gel as 
described [16], and then transferred to a nylon 
filter. After baking at 80°C for 2 h, the filter was 
prehybridized at 65°C for several hours in a sealed 
plastic bag containing 6 x SSC (1 x SSC is 0.15 M 
114 
NaCl, 15 mM Na citrate), 1% SDS. Hybridization 
was carried out at 65°C overnight in 6 x SSC, 1% 
SDS, 20pg/ml of heat denatured herring sperm 
DNA, containing the PSTI cDNA probe (l-2 x 
lo6 cpm/ml) described above. After the hybridiza- 
tion, the filter was rinsed at room temperature in 
2 X SSC, 1% SDS, washed twice at 65°C in the 
above solution for 30 min and then rinsed at room 
temperature in 0.1 x SSC. 
2.6. Primer extension analysis 
A 17-nucleotide single-stranded fragment 
(fig.2B; position 30-46) was synthesized as a 
primer by a,&cyanoethyl phosphoramidite method 
[ 171, and the 5 ‘-end was labeled with 32P, After 
heating at 65’C for 5 min, hybridization was done 
in a 30 ~1 reaction mixture containing 40 mM 
Pipes (pH 6.8), 0.4 M NaCl, 1 mM EDTA, 2 mM 
Na, 0.2% SDS, 1Opg of mRNA, and 0.5 pmol of 
5 ‘-end labeled primer at 37°C for 5 h. Next, 
reverse transcription was carried out in a 100~1 
reaction mixture containing 50 mM Tris (pH 8.0), 
140 mM KCl, 10 mM MgCL, 10 mM DTT, 
0.5 mM of each dNTP, 2400 U/ml of RNase in- 
hibitor, 300 U/ml of reverse transcriptase (RAV-2, 
Takara Shuzo, Kyoto, Japan) at 42°C for 1 h. 
Following phenol extraction and ethanol 
precipitation, the primer extension products were 
electrophoresed in a thin 6% polyacrylamide-8 M 
urea gel. 
3. RESULTS AND DISCUSSION 
We first examined the expression of PSTZ in 
various neoplastic tissues by Northern blottings. 
The results are shown in table 1. In three lung 
cancer cases (LC 2, LC 7, LC 19), all of which were 
adenocarcinomas, and one case of sigmoid colon 
polyp (CC 5), we detected the transcripts which 
hybridized to the PSTI cDNA probe. Among the 
ten cases of lung adenocarcinomas, five were the 
well differentiated type and the rest were the 
moderately differentiated type. Interestingly, all 
the PSTI-positive adenocarcinomas were the well 
differentiated type. Representative Northern blot 
profiles of the lung cancers are shown in fig.1. In 
lane 4 (adenocarcinoma, LC 19) a hybridizing 
band of about 530 nucleotides was detected. This 
size coincides with that of PSTI mRNA in the pan- 
creas (lane 1). The relative content of this 
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Table 1 
Summary of Northern blot analyses for PSTZ expression 
in various neoplastic tissues 
Organ Histology No. of No. of 
cases PSTI- 
positive 
cases 
Lung adenocarcinoma 10 3 
squamous cell carcinoma 3 0 
large cell carcinoma 1 0 
small cell carcinoma 2 0 
carcinoid 1 0 
Colon adenocarcinoma 4 0 
villous polyp 1 1 
Stomach adenocarcinoma 2 0 
Northern blot hybridization was done using PSTI cDNA 
pYIAM82 as a probe. For details, see section 2. PSTI- 
positive cases, viz. three lung cancers and one colon 
polyp were designated as LC 2, LC 7, LC 19, and CC 5, 
respectively 
transcript was estimated to be about l/50 of PSTZ 
mRNA in the pancreas. In three other PSTI- 
positive cases, the size and the level of the 
transcripts were essentially the same as those of 
this example (not shown). Other lanes, including 
lane 9 where 5 pug normal lung mRNA was used, 
showed no detectable bands. 
Two cDNA libraries were constructed with Agt 10 
from two tumor tissue mRNAs obtained from a 
lung adenocarcinoma (LC 19) and a sigmoid colon 
polyp (CC 5). Out of 10000 plaques from each 
library, we obtained two clones each that showed 
positive signals with PSTI cDNA probe. They were 
designated ATIL-1, ATIL-3 (from LC 19), and 
ATIC-1, hTIC-3 (from CC 5), and the inserts were 
found to be 384, 374, 233 and 295 nucleotides, 
respectively, including poly(A) (fig.2A). 
Before comparing the sequences of these inserts 
with that of pancreatic PSTI cDNA, we reexamin- 
ed the nucleotide sequence of the published PSTZ 
cDNA data [B], and found that some errors needed 
to be corrected. The corrected nucleotide sequence 
of the PSTZcDNA prepared from pancreas mRNA 
is shown in fig.2B. The PSTZ cDNA consists of a 
237-nucleotide amino acid coding region, a 
60-nucleotide 5 ’ -non-coding region and a 
8 1 -nucleotide 3 ’ -non-coding region. The insert of 
Fig. 1. Northern blot profiles of mRNAs from lung 
cancer tissues using PSTI cDNA as a probe. In lane 1, 
0.02 pg of pancreatic mRNA was used as a control. In 
lanes 2-8, mRNAs (5 pug) prepared from tumor tissues 
of LC 13 (adenoca.), LC 17 (adenoca.), LC 19 
(adenoca.), LC 34 (squamous cell ca.), LC 35 (squamous 
cell ca.), LC 20 (large cell ca.) and LC 23 (small cell ca.) 
were employed. In lane 9, 5 pg of mRNA from normal 
lung tissue was used. The mRNAs were denatured, 
electrophoresed and subjected to Northern blotting as 
described in section 2. Autoradiography was performed 
for 5 days at -70°C with an intensifying screen. 
ATIC-1, which is the longest among the four clones 
obtained, covered the entire PSTZ cDNA and was 
shown to be completely identical to the pancreatic 
PST1 by sequence analysis (fig.2B). Although the 
other three clones, hTIC-3, ATIL-1, XTIL-3, had 
only partial PST1 cDNA inserts, their nucleotide 
sequences also coincided completely with that of 
the pancreatic PSTZ cDNA. 
To compare the transcription start points of the 
PSTZ gene in the pancreas and the neoplastic 
tissues, primer extension analyses were done using 
a synthetic ll-nucleotide (fig.2B) as a primer on 
mRNA templates obtained from the pancreas. The 
results shown in fig.3 demonstrate that the PSTI 
gene has one major transcription start point (- 60) 
and three (-94, -70, -39) or more minor 
transcription start points. S1 nuclease mapping 
results agreed well with these results (not shown). 
Recently, we characterized the human PSTI gene 
and showed that it has no sequence typical for the 
promoter in the 5’-flanking region (Horii et al., in 
115 
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PSTI cDNA 
hTIC-1 
ATIC- 
B 
tl 
ATIL-3 
‘+123 
I 
1 1 PO~YA 
ATIC- 
-60 r 
ATIC- 
GAAGAGACGTGGTAAGTGCGGTGCAGTTTTCAACTGACCTCTGGACGCAGAACTTCAGCC 
* 
+61 r ATIL-1 
ACT GGA GCT GAC TCC CTG GGA AGA GAG GCC AAA TGT TAC AAT GAA CTT AAT GGA TGC ACC 
Thr Gly Ala Asp Ser Leu Gly Arg Glu Ala Lys Cys Thr Asn Glu Leu Asn Gly Cys Thr 
tl21 r ATIL-3 
t181 
AAG ATA TAT GAC CCT GTC TGT GGG ACT GAT GGA AAT ACT TAT CCC AAT GAA TGC GTG TTA 
Lys Ile Tyr Asp Pro Val Cys Gly Thr Asp Gly Asn Thr Tyr Pro Asn Glu Cys Val Leu 
t237 
CAG ACT TCT ATC CTC ATT CAA AAA TCT GGG CCT TGC m 
Gln Thr Ser Ile Leu Ile Gln Lys Ser Gly Pro Cys 
+31 a 
TGT TTT GAA GGT CGG AAA CGC 
Cys Phe Glu Asn Arg Lys Arg 
GAACCAAGGTTTTGAAATCCCATCAGG TCACCGCGAGGCCTATTGTTGAATAAATGTATCTGAATATCAn 
m AAG GTA ACA GGC ATC TTT CTT CTC AGT GCC TTG GCC CTG TTG AGT CTA TCT GGT AAC 
Met Lys Val Thr Gly Ile Phe Leu Leu Ser Ala Leu Ala Leu Leu Ser Leu Ser Gly Asn 
Fig.2. (A) Restriction map of PSTI cDNA clones isolated from cDNA libraries prepared from mRNAs of neoplastic 
tissues. hTIC-1 and ATIC- are clones isolated from the tumor tissue cDNA library of sigmoid colon polyp (CC S), and 
XTIL-1 andhTIL-3 are those from lung adenocarcinoma (LC 19). Cleavage sites by some restriction enzymes are shown. 
The white horizontal bar represents the amino acid-coding region. (B) Corrected nucleotide sequence of the PSTZ cDNA 
and deduced amino acid sequence. The 5 ‘-ends of the PSTZ cDNA clones prepared from two different neoplastic tissues 
are also shown. A few errors in the nucleotide sequence of the PSTZ cDNA previously published in [8] have been 
corrected. The translation initiation codon (ATG) and termination codon (TGA) are boxed. AATAAA represents the 
poly(A) additional signal and An represents the poly(A) stretch. The numbers start from the first base of ATG. PSTZ 
cDNA clones obtained from neoplastic tissues cover the regions between the horizontal arrows and poly(A). The 
underlined section marked with an asterisk represents the region corresponding to the synthesized 17-nucleotide primer 
used for primer extension analyses. 
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Fig.3. Primer extension analysis for defining 
transcription start point of PSTZ mRNA. The 32P- 
labeled synthetic 17-nucleotide was hybridized to 
mRNAs and extended with reverse transcriptase as 
described in section 2. In lanes 1 and 2, 10,~g each of 
human pancreatic mRNA and rat liver mRNA were 
used. Lanes AGCT show the dideoxy sequencing ladder 
as a size marker. Autoradiography was performed at 
- 70°C for 4 h. The numbers indicate the nucleotide 
number from the first base of the ATG translation 
initiation codon. 
EcoR I B&II PVUII 
N T N T N ‘I’ 
kbp. 
23 
9.4 
6.5 
4.3 
2.2 
2.0 
Fig.4. Southern blot analyses of the PSTZ gene in tumor 
tissue. N indicates the DNA isolated from the non- 
cancerous part of lung tissue dissected with lung 
adenocarcinoma (LC 19), and T indicates the DNA 
isolated from the tumor tissue (LC 19) that was shown 
to express PSTZ. DNAs (10 ag) were digested with 
restriction enzymes indicated at the top of the figure, 
electrophoresed, and subjected to Southern blotting 
analyses using the PSTZ cDNA as a probe. For details, 
see section 2. Autoradiography was performed at 
-70°C for 4 days with an intensifying screen. Size 
markers (in kb) are the Hind111 digests of h phage DNA. 
preparation). Transcription of the PSTZ gene may 
start at multiple points because of this atypical 
promoter structure. Because of limited tissue supp- 
ly, primer extension analyses using mRNAs of 
neoplastic tissues could not be done. However, 
XTIC-1 carries the insert that covers just from the 
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- 60 to the poly(A) tail. Therefore, the transcrip- 
tion start site in this neoplastic tissue seems to be 
the same as that acting in the normal pancreas. 
In some lung cancers, elevated expression of an 
oncogene such as c-myc [ 181 or N-myc [ 191, ac- 
companied by gene amplification, has been 
reported. An intriguing possibility is that PST1 ex- 
pression in lung cancer might be the result of PST1 
gene activation due to gene amplification or rear- 
rangement. Southern blot analyses of DNA ob- 
tained from the LC 19 sample and its normal 
counterpart DNA were performed. The results are 
shown in fig.4. We can see that the PSTZ gene in 
tumor tissue underwent neither amplification nor 
rearrangement. 
The present study clearly demonstrated that in 
some benign or malignant neoplastic tissues, the 
PSTI gene is transcribed in the same manner as in 
normal pancreas. This does not necessarily mean 
that the biological function of the tumor-produced 
PST1 is the same with that of pancreas-produced 
PSTI. 
Several investigators have reported that eleva- 
tion of proteolytic activity can be seen in some 
cancerous tissues [20,21], indicating the possibility 
that tumor cells produce some protease inhibitors 
in self-defense. Recently, McKeehan et al. [22] 
isolated two human endothelial cell growth factors 
from human hepatoma cells, and showed that 25 
NHz-terminal amino acid residues of one of the 
growth factors were identical with those of human 
PSTI. In addition, Ogawa et al. [23] observed that 
human PST1 can stimulate 13H]thymidine incor- 
poration into DNA in human fibroblasts. These 
results strongly suggest that PST1 may act as a 
growth factor under some circumstances. One at- 
tractive possibility is that the tumor-produced 
PST1 also acts as a growth factor-like substance in 
the course of tumor development. In some tumor- 
bearing patients, the serum PST1 level is high, 
although the tumor tissue itself has no significant 
level of immunoreactive PST1 [24]. In another 
case, patients display high serum PST1 level even 
after resection of the tumor (unpublished). The 
high PST1 levels in these cases may be due to pro- 
duction of PST1 as an acute phase reactant from 
tissues other than the malignant one. Further ex- 
periments are needed to clarify these points and to 
shed light on other possible biological functions 
associated with PSTI. 
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